ENDRA Life Sciences Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ENDRA Life Sciences Inc. on December 21, 2020, regarding events occurring on December 16, 2020. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Ann Arbor, Michigan.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on a material definitive agreement and a regulatory disclosure correction.
Material Changes
- Agreement Extension: On December 16, 2020, the Company entered into Amendment 4 to its Collaborative Research Agreement with General Electric Company (GE). This amendment extends the term of the agreement to December 16, 2022.
- Disclosure Correction: The Company issued a press release on December 21, 2020, which incorrectly stated the agreement extension ended on December 16, 2023. This filing corrects the end date to December 16, 2022.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of new risks or contingencies beyond the correction of the agreement term date. The text of Amendment 4 is incorporated by reference as Exhibit 10.1.
Key Facts for Investor Verification
- Verify the exact end date of the Collaborative Research Agreement with GE is December 16, 2022, not 2023 as previously reported in the press release.
- Review Exhibit 10.1 (Amendment 4) for specific terms, obligations, and financial considerations associated with the extension.
- Confirm the status of the Company's emerging growth company designation and its impact on future reporting requirements.